ClinicalTrials.gg
Not yet recruitingNCT07474805ORReMexUpdated Nov 10, 2026

Outcomes of Renal Replacement in Mexico

An observational study in Chronic Kidney Disease - Stage V and Chronic Kidney Disease on Hemodialysis, sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Observational

How we know

Updated Nov 10, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
290
Sex
All
01

Study summary

A descriptive, observational, prospective, multicenter study aimed at describing the main clinical outcomes of patients with chronic kidney disease receiving any form of renal replacement therapy in Mexico.

02

Conditions studied

  • Chronic Kidney Disease - Stage V
  • Chronic Kidney Disease on Hemodialysis

Keywords

  • Chronic kidney disease
  • Renal replacement therapy
  • Clinical outcomes
03

In context

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

This study's planned enrollment of 290 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is the lead sponsor of 145 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic kidney disease undergoing hemodialysis or peritoneal dialysis in the units participating in the project

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to participate and provision of written
  • Diagnosis of chronic kidney disease and treatment with hemodialysis or peritoneal dialysis for ≥3 months
  • Availability of a medical record containing information on the study variables
  • Receiving care at one of the participating centers

Exclusion criteria

Exclusion Criteria:

  • \<3 months due to a cause unrelated to chronic kidney disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
290 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • CKD on RRT

    Patients with chronic kidney disease undergoing renal replacement therapy (RRT) in Mexico

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    The occurrence of death from any cause during the follow-up period, as documented in the patient's medical record

    Time frame: From enrollment in the study until death from any cause or end of follow-up, assessed up to 3 years.

Secondary outcomes

  1. Hospitalizations per patient-year

    The number of hospitalizations recorded during the study follow-up, expressed per patient-year

    Time frame: From enrollment until the end of follow-up, assessed up to 3 years

  2. Infection rate

    The number of documented infection episodes during the follow-up period, as recorded in the medical records, expressed per patient-year.

    Time frame: From enrollment until the end of follow-up, assessed up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — It has not yet been determined whether individual participant data will be shared. Decisions regarding data sharing will be made after completion of the study and publication of the primary results, in accordance with institutional policies and applicable regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 35 months is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Apr 2026 → Jan 2027, primary completion Apr 2026 → Dec 2029 and completion Apr 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 16, 2026
StartEst.
Jan 2027was Apr 2026
Primary completionEst.
Dec 2029was Apr 2026
CompletionEst.
Dec 2029was Apr 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 2026→Jan 2027
Nov 10, 2026
Primary completion
Apr 2026→Dec 2029
Nov 10, 2026
Study completion
Apr 2029→Dec 2029
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date Apr 2026→Jan 2027
    Primary completion Apr 2026→Dec 2029
    Study completion Apr 2029→Dec 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07474805
Responsible party
Olynka Vega (Attending Physician, Department of Nephrology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran) — Principal investigator
First posted
Mar 16, 2026
Start date
Jan 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Olynka Vega Vega, MD, MSc
Contact
olynkavega@hotmail.com
+5215548039428
Yazmin Alejandra Mercado Hernandez, MD
Contact
yazale1992@hotmail.com
+5215520353821

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion